This document is a Form 16 certificate issued by DelveInsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes the salary paid, taxes deducted, and other income. The key details are:
- Gross salary paid was Rs. 3,71,540
- Standard deduction of Rs. 50,000 was claimed
- Total income chargeable was Rs. 3,21,540
- Total deductions under Chapter VI-A were Rs. 19,812
- Net tax payable was Rs. 0
The document is a Form 16 certificate issued by Delveinsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes that a total amount of Rs. 371540 was paid to Yashveer Bhardwaj from April 2021 to March 2022, but no tax was deducted at source by Delveinsight Business Research LLP. The certificate is signed by Vishal Agrawal on behalf of Delveinsight Business Research LLP.
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
For More Information- https://www.delveinsight.com/asco-conference/article/roche-glofitamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Genmab/Abbvie presented spectacular findings from arm 2 of the EPCORE NHL-2 (Phase Ib/II) trial in the patients with R/R Follicular Lymphoma.
Read More- https://www.delveinsight.com/asco-conference/article/genmab-abbvies-epcoritamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Teclistamab is a bispecific antibody that targets BCMA [B-cell maturation agent] and CD3. BCMA is highly expressed on myeloma cells and has limited expression on normal tissue, making it an ideal target for anti-myeloma strategies
Read More- https://www.delveinsight.com/asco-conference/article/teclistamab-asco?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
This document is a Form 16 certificate issued by DelveInsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes the salary paid, taxes deducted, and other income. The key details are:
- Gross salary paid was Rs. 3,71,540
- Standard deduction of Rs. 50,000 was claimed
- Total income chargeable was Rs. 3,21,540
- Total deductions under Chapter VI-A were Rs. 19,812
- Net tax payable was Rs. 0
The document is a Form 16 certificate issued by Delveinsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes that a total amount of Rs. 371540 was paid to Yashveer Bhardwaj from April 2021 to March 2022, but no tax was deducted at source by Delveinsight Business Research LLP. The certificate is signed by Vishal Agrawal on behalf of Delveinsight Business Research LLP.
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
For More Information- https://www.delveinsight.com/asco-conference/article/roche-glofitamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Genmab/Abbvie presented spectacular findings from arm 2 of the EPCORE NHL-2 (Phase Ib/II) trial in the patients with R/R Follicular Lymphoma.
Read More- https://www.delveinsight.com/asco-conference/article/genmab-abbvies-epcoritamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Teclistamab is a bispecific antibody that targets BCMA [B-cell maturation agent] and CD3. BCMA is highly expressed on myeloma cells and has limited expression on normal tissue, making it an ideal target for anti-myeloma strategies
Read More- https://www.delveinsight.com/asco-conference/article/teclistamab-asco?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.
For More Inquiry- https://www.delveinsight.com/infographics/primary-hyperoxaluria-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Regional subgroup analysis of the Phase III TOPAZ-1 clinical trial of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (Abstract # 4075)
Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
For More Information- https://www.delveinsight.com/infographics/chronic-obstructive-pulmonary-disease-copd-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographicc
Arcellx, Gracell Biotechnologies, and Oricell have demonstrated impressive clinical outcomes at ASCO 2022, posing a challenge to J&J/Legend Biotech’s and BMS's leading CAR-T cell therapies.
https://www.delveinsight.com/asco-conference/article/competitive-therapeutic-landscape-of-multiple-myeloma?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system.
https://www.delveinsight.com/infographics/multiple-sclerosis-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Common Warts, also known as Verruca Vulgaris, is caused by non-malignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca Vulgaris.
CEL-SCI presented results from its Phase III IT-MATTERS study evaluating Multikine as a neoadjuvant therapy for advanced primary squamous cell carcinoma of the head and neck at ASCO 2022. The study showed a 14% absolute improvement in overall survival for lower-risk patients, representing the first positive randomized results in over 25 years for this population. Based on these results, CEL-SCI plans to file a BLA with the FDA for approval of Multikine for this indication.
A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched: https://www.delveinsight.com/asco-conference/article/dlbcl-preview
Contact Us
Yash
info@delveinsight.com
The document summarizes three reports by DelveInsight on Vimpat API, Wet AMD Epidemiology, and Xarelto API. The Vimpat report provides details on the drug's manufacturer, mechanism of action, clinical trials, sales forecasts and patents. The Wet AMD report describes the disease, prevalence in the US expected to grow to 3 million cases by 2020, and risk factors like increasing with age. The Xarelto report similarly provides manufacturer details, mechanism, clinical trials, sales forecasts and competitive landscape. All reports use primary and secondary research from various sources.
Type 1 Diabetes,
Type 1 Diabetes market,
Type 1 Diabetes market report,
Type 1 Diabetes market research,
Type 1 Diabetes market share,
Type 1 Diabetes market size,
Type 1 Diabetes market trends,
Type 1 Diabetes market insights,
Type 1 Diabetes treatment market,
Type 1 Diabetes market drugs,
Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.
For More Inquiry- https://www.delveinsight.com/infographics/primary-hyperoxaluria-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Regional subgroup analysis of the Phase III TOPAZ-1 clinical trial of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (Abstract # 4075)
Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
For More Information- https://www.delveinsight.com/infographics/chronic-obstructive-pulmonary-disease-copd-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographicc
Arcellx, Gracell Biotechnologies, and Oricell have demonstrated impressive clinical outcomes at ASCO 2022, posing a challenge to J&J/Legend Biotech’s and BMS's leading CAR-T cell therapies.
https://www.delveinsight.com/asco-conference/article/competitive-therapeutic-landscape-of-multiple-myeloma?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system.
https://www.delveinsight.com/infographics/multiple-sclerosis-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Common Warts, also known as Verruca Vulgaris, is caused by non-malignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca Vulgaris.
CEL-SCI presented results from its Phase III IT-MATTERS study evaluating Multikine as a neoadjuvant therapy for advanced primary squamous cell carcinoma of the head and neck at ASCO 2022. The study showed a 14% absolute improvement in overall survival for lower-risk patients, representing the first positive randomized results in over 25 years for this population. Based on these results, CEL-SCI plans to file a BLA with the FDA for approval of Multikine for this indication.
A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched: https://www.delveinsight.com/asco-conference/article/dlbcl-preview
Contact Us
Yash
info@delveinsight.com
The document summarizes three reports by DelveInsight on Vimpat API, Wet AMD Epidemiology, and Xarelto API. The Vimpat report provides details on the drug's manufacturer, mechanism of action, clinical trials, sales forecasts and patents. The Wet AMD report describes the disease, prevalence in the US expected to grow to 3 million cases by 2020, and risk factors like increasing with age. The Xarelto report similarly provides manufacturer details, mechanism, clinical trials, sales forecasts and competitive landscape. All reports use primary and secondary research from various sources.
Type 1 Diabetes,
Type 1 Diabetes market,
Type 1 Diabetes market report,
Type 1 Diabetes market research,
Type 1 Diabetes market share,
Type 1 Diabetes market size,
Type 1 Diabetes market trends,
Type 1 Diabetes market insights,
Type 1 Diabetes treatment market,
Type 1 Diabetes market drugs,
1. ASCO 2022: Daiichi’s Patritumab Highlight
Results from the phase I/II study of patritumab deruxtecan, a HER3-directed
antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic
breast cancer (MBC)
Patritumab deruxtecan (HER3-DXd) is one of three lead DXd Daiichi Sankyo ADCs
in the oncology pipeline. Designed using Daiichi Sankyo’s proprietary DXd ADC
technology, patritumab deruxtecan comprises a fully human anti-HER3 IgG1
monoclonal antibody attached to topoisomerase I inhibitor payload (an exatecan
derivative, DXd) via a stable tetrapeptide-based cleavable linker.
At a median follow-up of 31.9 months (range, 15-56), the objective response rate
(ORR) was 30.1% in patients with HER3-high or HER3-low, HR-positive/HER2-
negative MBC. All responses were partial responses (PR). The median duration of
response (DOR) in this cohort was 7.2 months, with the median progression-free
survival (PFS) was 7.4 months, and the median overall survival (OS) was 14.6
months.
In patients with HER3-high metastatic TNBC, ORR was 22.6%, and all responders
had PR. The median DOR was 5.9 months, with a median PFS of 5.5 months and a
median OS of 14.6 months.
In patients with HER3-high, HER2-positive MBC, the ORR was 42.9%, and again all
responses were partial. The median DOR was 8.3 months with a median PFS of
11.0 months and median OS of 19.5 months.
“Results from this trial show that patritumab deruxtecan produces clinically
meaningful and durable antitumor activity in patients and further study is
warranted to further evaluate the efficacy and safety of this HER3-directed ADC
across patients with HR-positive/HER2-negative, HER2-positive, and TNBC.” –
Expert Opinion 1
“Of course this begs the question of where we go from here but clearly ADCs are
the BOMB - huge advance in chemo delivery.” – Expert Opinion 2
“Exciting clinical benefit rate across all breast cancer subtypes. The future looks
bright.”- – Expert Opinion 3
CONCLUSION
2. Daiichi Sankyo has developed three ADCs, out of which it licensed two ADCs to
AstraZeneca – but has kept the third, patritumab deruxtecan breast cancer, for
itself. The drug has been granted Breakthrough Designation from the FDA to treat
patients with metastatic or locally advanced EGFR-mutated non–small cell lung
cancer (NSCLC). The results presented at ASCO 2022 show the drug’s potential in
metastatic Breast Cancer.
The anti-Her3 space is focusing on Hummingbird Bioscience’s HMBD-001, which
recently went into the clinic in HER3-positive solid tumors. GSK’s GSK2849330 has
also produced intriguing results in NRG1 fusion cancers but is not currently listed
on the company’s pipeline. Moreover, Merus’s Her2/Her3-targeting bispecific,
zenocutuzumab, had significant results at ASCO 2022.
Companies- Gilead, Daiichi Sankyo, Sanofi, AstraZeneca, Eli Lilly, Radius Health,
Sermonix Pharmaceuticals, Roche, Veru Pharma, and others.
Read Market Research Reports 2022
Medical Marijuana Market | Sarcopenia Market | Tourette Syndrome Market |
Oncolytic Virus Cancer Therapy Pipeline | Shigellosis Market | Myopia Treatmen
t Devices Market | Urology Ultrasounds Devices Market | Viscosupplementation
Devices Market | Peripheral Nerve Repair Devices Market | NPC
Market | Inflammatory Pain Market | Venous Thromboembolism Market | Cann
abis Use Disorder Market | Sepsis Market | Neurodermatitis Market | Neuroend
ocrine Tumors Market | Microscopy Device Market | Surgical Mask & Respirator
Market | Radiodermatitis Market